SCHEMBL8251024

SCHEMBL8251024

Fc1cc(CN2CCOCC2)ccc1N1CCNCC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.47
HRH3 Q9Y5N1 2/20 0.46
KDM4E B2RXH2 1/20 0.44
HSD17B10 Q99714 1/20 0.44
NCF1 P14598 1/20 0.43
PARP1 P09874 2/20 0.43
HTT P42858 2/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP2A13 Q16696 1/20 0.42
NPC1 O15118 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
KCNH2 Q12809 1/20 0.41
WDR5 P61964 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8259609 0.87 ALDH1A1 (0.58) HRH3KDM4EHSD17B10PARP1HTT
SCHEMBL28129037 0.85 ALDH1A1 (0.54) HRH3KDM4EHSD17B10PARP1HTT
Hydrochloric Acid SCHEMBL17422312 0.82 HRH3 (0.42) HRH3NCF1ALDH1A1CYP2A13SMN1; SMN2
SCHEMBL12828065 0.78 HTR6 (0.46) ALDH1A1SMN1; SMN2
SCHEMBL2270689 0.78 HRH3 (0.61) HRH3ALDH1A1SMN1; SMN2
SCHEMBL8257644 0.77 LGMN (0.50) HSD17B10ALDH1A1NPC1SMN1; SMN2TP53
SCHEMBL8250737 0.77 HTR6 (0.45) ALDH1A1SMN1; SMN2
SCHEMBL18052714 0.77 HTR6 (0.50) HRH3ALDH1A1KCNH2
SCHEMBL23943839 0.75 HTT (0.54) KDM4EHTTALDH1A1SMN1; SMN2TSHR
SCHEMBL2921989 0.75 ALDH1A1 (0.69) HRH3KDM4EHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368449-B2 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION (US) 2008-05-06 US disclosed
US-7368449-B2 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION (US) 2008-05-06 US disclosed
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION 2004-11-04 US disclosed
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists ADORA2A, ADORA3, ADORA1 PIK3CA 1023/4885HRH3 60/4885KDM4E 4567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.